Results 81 to 90 of about 169,093 (102)

Abstract 3328: Antitumor activity of BLU-945 and BLU-701 as single agents and in combination in EGFR L858R-driven models of NSCLC

Cancer Research, 2022
BACKGROUND: Lung cancer is the leading cause of cancer death globally. EGFR mutations are the most common genomic drivers of non-small cell lung cancer (NSCLC), occurring in ~17% and up to 50% of Caucasian and Asian patients, respectively, with exon 19
L. Tavera, S. Schalm, John L. Campbell, Jian Guo, Clare Medendorp, Maxine Chen, F. Albayya, T. Dineen, Zhuo Zhang, M. Iliou, Ebby Job, Nisha Perez, Y. Timsit, Scott L. Wardwell, Katie McGinn, R. Woessner, C. Conti   +16 more
semanticscholar   +1 more source

A phase 1/2 study of the highly selective EGFR inhibitor, BLU-701, in patients with EGFR-mutant non–small cell lung cancer (NSCLC).

Journal of Clinical Oncology, 2022
TPS9142 Background: Although 3rd-generation tyrosine kinase inhibitors (TKIs), such as osimertinib, are highly effective in front-line metastatic EGFR-mutated ( EGFRm) NSCLC, treatment resistance ultimately occurs, including the emergence of the on ...
A. Spira, D. Spigel, D. Camidge, A. D. de Langen, T. Kim, K. Goto, Y. Elamin, Elaine Shum, K. Reckamp, J. Rotow, S. Goldberg, S. Gadgeel, T. Leal, F. Albayya, Sarah Fitzpatrick, M. Louie-Gao, J. Parepally, A. Zalutskaya, H. Yu   +18 more
semanticscholar   +1 more source

Abstract 1262: BLU-701 is a highly potent, brain-penetrant and WT-sparing next-generation EGFR TKI for the treatment of sensitizing (ex19del, L858R) and C797S resistance mutations in metastatic NSCLC

Experimental and Molecular Therapeutics, 2021
BACKGROUND: Non-small cell lung cancer (NSCLC) represents 80% of lung cancers, the second leading cause of cancer deaths globally. Mutations in the kinase domain of the epidermal growth factor receptor (EGFR) are genomic drivers in a molecular sub-type ...
C. Conti, John L. Campbell, R. Woessner, Jian Guo, Y. Timsit, M. Iliou, Scott D. Wardwell, A. Davis, Sharon Chicklas, J. Hsieh, Meredith S Eno, O. Ahmad, D. Fernando, Kevin A Barvian, Joseph L. Kim, S. Kazmirski, E. Perola, T. Dineen, Victoria Brown, T. Guzi, Ayşegül Özen, F. Stevison, C. Utt, Clare Medendorp, R. Meißner, M. Dorsch, K. Hoeflich   +26 more
semanticscholar   +1 more source

LncRNA KCNQ1OT1 accelerates fracture healing via modulating miR‐701‐3p/FGFR3 axis

The FASEB Journal, 2020
Emerging evidence highlights the role of the long noncoding RNA (lncRNA) KCNQ1OT1 in fracture healing. Osteoblast proliferation, migration, and survival are pivotal during this process.
Lang Chen, Y. Xiong, Chenchen Yan, Wu Zhou, Y. Endo, Hang Xue, Yiqiang Hu, Liangcong Hu, Xingzhu Leng, Jing Liu, Ze Lin, B. Mi, Guohui Liu   +12 more
semanticscholar   +1 more source

Clinical and epidemiological characteristics of childhood vitiligo: a study of 701 patients from Brazil

International Journal of Dermatology, 2020
Vitiligo is an acquired pigmentary disorder that affects approximately 0.5–2% of the world's population, and 25% of cases begin before 10 years of age. Although prevalent, there are few studies on the characterization of childhood vitiligo.
Clarissa P.S. Martins, A. Hertz, P. Luzio, P. Paludo, L. Azulay‐Abulafia   +4 more
semanticscholar   +1 more source

The direct effect of the international standard on auditing – 701 requirements on audit profession concerning the reimbursement costs: case study of Jordanian finance industry

Asian Journal of Accounting Research
PurposeThe objective of this study is to present novel evidence regarding the impact of the Key Audit Matters (KAM) disclosure requirements of International Standard on Auditing – 701 (ISA) on the auditing profession concerning reimbursement costs in ...
E. Alharasis
semanticscholar   +1 more source

Radiosynthesis and preclinical evaluation of [11 C]Cimbi-701 - Towards the imaging of cerebral 5-HT7 receptors.

Journal of labelled compounds & radiopharmaceuticals, 2020
PURPOSE The serotonin 7 (5-HT7 ) receptor is suggested to be involved in a broad variety of CNS disorders, but very few in vivo tools exist to study this important target.
Elina T L 'Estrade, Vladimir Shalgunov, Fraser G. Edgar, Martin G Strebl-Bantillo, Mengfei Xiong, François Crestey, R. Neelamegam, A. Dyssegaard, S. Lehel, M. Erlandsson, T. Ohlsson, J. Hooker, G. Knudsen, M. Herth, H. D. Hansen   +14 more
semanticscholar   +1 more source

Clinical update related to the first-in-human trial of SYS6002 (CRB-701), a next-generation nectin-4 targeting antibody drug conjugate.

Journal of Clinical Oncology
3151 Background: SYS6002 (CRB-701) is a novel, nectin-4 targeting antibody drug conjugate (ADC) that take advantage of a third generation, site-specific cleavable linker with novel conjugation chemistry.
D. Ye, Jian Zhang, Hua Yang, Jin Yang, Tongsen Zheng, Hongmei Sun, Yuping Sun, Guiling Li, Funan Liu, Xuechao Wan, Lan Ge, G. Sun, Xiao Zhang, Lei Wang, Rachael Brake   +14 more
semanticscholar   +1 more source

Phase 1 dose escalation of SYS6002 (CRB-701), a next-generation nectin-4 targeting antibody drug conjugate (ADC).

Journal of Clinical Oncology
622 Background: Linker-conjugation of an ADC is a key feature in optimizing highly active and well tolerated agents. For maximal intra-tumoral delivery, linkers need to be highly stable in the systemic circulation yet allow for efficient drug release at ...
D. Ye, Jian Zhang, Hua Yang, Jin Yang, Tongsen Zheng, Hongmei Sun, Xuechao Wan, Ge Lan, G. Sun, Xiao Zhang   +9 more
semanticscholar   +1 more source

Fierce-21: Phase II study of vofatmab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC).

Journal of Clinical Oncology, 2019
409 Background: Patients (pts) with mUC who have failed platinum-based chemotherapy have a poor prognosis. About 20% of them usually respond to immune checkpoint inhibitors (ICI).
A. Necchi, D. Castellano, B. Mellado, S. Pang, Y. Urun, S. Park, U. Vaishampayan, G. Currie, Esteban Abella-Dominicis, S. Pal   +9 more
semanticscholar   +1 more source